DEA
Easterly Government Properties, Inc.
REIT - Office
Market Cap$1.08B
5Y Perf.-62.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
DEA vs GMRE
Revenue, margins, valuation, and 5-year total return — side by side.
GMRE
Global Medical REIT Inc.
REIT - Healthcare Facilities
Market Cap$94M
5Y Perf.-35.4%
DEA vs GMRE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | DEA | GMRE |
|---|---|---|
| Industry | REIT - Office | REIT - Healthcare Facilities |
| Market Cap | $1.08B | $94M |
| Revenue (TTM) | $344M | $148M |
| Net Income (TTM) | $15M | $2M |
| Gross Margin | 49.7% | 68.8% |
| Operating Margin | 24.9% | 24.9% |
| Forward P/E | 69.5x | 595.7x |
| Total Debt | $1.68B | $654M |
| Cash & Equiv. | $23M | $7M |
DEA vs GMRE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
DEA
GMRE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Easterly Government… (DEA) | 100 | 37.2 | -62.8% |
| Global Medical REIT… (GMRE) | 100 | 64.6 | -35.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DEA vs GMRE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: DEA leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Global Medical REIT Inc. is the stronger pick specifically for capital preservation and lower volatility and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
DEA
Easterly Government Properties, Inc.
The Real Estate Income Play
DEA carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 11.3%, EPS growth -37.0%, 3Y rev CAGR 4.6%
- 11.3% FFO/revenue growth vs GMRE's -1.8%
- Lower P/E (69.5x vs 595.7x)
Best for: growth exposure
GMRE
Global Medical REIT Inc.
The Real Estate Income Play
GMRE is the clearest fit if your priority is income & stability and long-term compounding.
- Dividend streak 5 yrs, beta 0.48, yield 63.5%
- 308.1% 10Y total return vs DEA's -10.5%
- Lower volatility, beta 0.48, current ratio 0.03x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | DEA | 11.3% FFO/revenue growth vs GMRE's -1.8% |
| Value | DEA | Lower P/E (69.5x vs 595.7x) |
| Quality / Margins | DEA | 4.3% margin vs GMRE's 1.7% |
| Stability / Safety | GMRE | Beta 0.48 vs DEA's 0.51, lower leverage |
| Dividends | GMRE | 63.5% yield, 5-year raise streak, vs DEA's 9.0% |
| Momentum (1Y) | DEA | +21.4% vs GMRE's -0.3% |
| Efficiency (ROA) | DEA | 0.4% ROA vs GMRE's 0.2%, ROIC 2.1% vs 2.0% |
DEA vs GMRE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
DEA vs GMRE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLGMRELAGGINGDEA
DEAEasterly Government P…
1leads
GMREGlobal Medical REIT I…
3leads
6 Total Categories
CATEGORYLEADERvs DEAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DEA4/6
Valuation MetricsMultiples, price ratios, and targets
GMRE3/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
GMRE4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
GMRE2/2
Income & Cash Flow (Last 12 Months)
DEA leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
DEA is the larger business by revenue, generating $344M annually — 2.3x GMRE's $148M. Profitability is closely matched — net margins range from 4.3% (DEA) to 1.7% (GMRE). On growth, GMRE holds the edge at +18.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | DEAEasterly Governme… | GMREGlobal Medical RE… |
|---|---|---|
| RevenueTrailing 12 months | $344M | $148M |
| EBITDAEarnings before interest/tax | $203M | $95M |
| Net IncomeAfter-tax profit | $15M | $2M |
| Free Cash FlowCash after capex | $262M | $19M |
| Gross MarginGross profit ÷ Revenue | +49.7% | +68.8% |
| Operating MarginEBIT ÷ Revenue | +24.9% | +24.9% |
| Net MarginNet income ÷ Revenue | +4.3% | +1.7% |
| FCF MarginFCF ÷ Revenue | +76.2% | +12.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.6% | +18.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -55.4% | -166.2% |
DEA leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
GMRE leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
At 80.3x trailing earnings, DEA trades at a 30% valuation discount to GMRE's 115.3x P/E. On an enterprise value basis, GMRE's 8.3x EV/EBITDA is more attractive than DEA's 13.9x.
| Metric | DEAEasterly Governme… | GMREGlobal Medical RE… |
|---|---|---|
| Market CapShares × price | $1.1B | $94M |
| Enterprise ValueMkt cap + debt − cash | $2.7B | $741M |
| Trailing P/EPrice ÷ TTM EPS | 80.31x | 115.29x |
| Forward P/EPrice ÷ next-FY EPS est. | 69.52x | 595.67x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 13.85x | 8.35x |
| Price / SalesMarket cap ÷ Revenue | 3.21x | 0.68x |
| Price / BookPrice ÷ Book value/share | 0.77x | 0.17x |
| Price / FCFMarket cap ÷ FCF | 4.16x | — |
GMRE leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
Evenly matched — DEA and GMRE each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
DEA delivers a 1.1% return on equity — every $100 of shareholder capital generates $1 in annual profit, vs $0 for GMRE. GMRE carries lower financial leverage with a 1.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to DEA's 1.23x.
| Metric | DEAEasterly Governme… | GMREGlobal Medical RE… |
|---|---|---|
| ROE (TTM)Return on equity | +1.1% | +0.5% |
| ROA (TTM)Return on assets | +0.4% | +0.2% |
| ROICReturn on invested capital | +2.1% | +2.0% |
| ROCEReturn on capital employed | +3.6% | +5.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 1.23x | 1.18x |
| Net DebtTotal debt minus cash | $1.7B | $647M |
| Cash & Equiv.Liquid assets | $23M | $7M |
| Total DebtShort + long-term debt | $1.7B | $654M |
| Interest CoverageEBIT ÷ Interest expense | 1.18x | 1.14x |
Evenly matched — DEA and GMRE each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
GMRE leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GMRE five years ago would be worth $8,020 today (with dividends reinvested), compared to $6,215 for DEA. Over the past 12 months, DEA leads with a +21.4% total return vs GMRE's -0.3%. The 3-year compound annual growth rate (CAGR) favors GMRE at 1.8% vs DEA's -6.2% — a key indicator of consistent wealth creation.
| Metric | DEAEasterly Governme… | GMREGlobal Medical RE… |
|---|---|---|
| YTD ReturnYear-to-date | +11.4% | +6.9% |
| 1-Year ReturnPast 12 months | +21.4% | -0.3% |
| 3-Year ReturnCumulative with dividends | -17.4% | +5.6% |
| 5-Year ReturnCumulative with dividends | -37.9% | -19.8% |
| 10-Year ReturnCumulative with dividends | -10.5% | +308.1% |
| CAGR (3Y)Annualised 3-year return | -6.2% | +1.8% |
GMRE leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — DEA and GMRE each lead in 1 of 2 comparable metrics.
Risk & Volatility
GMRE is the less volatile stock with a 0.48 beta — it tends to amplify market swings less than DEA's 0.51 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DEA currently trades 93.4% from its 52-week high vs GMRE's 89.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DEAEasterly Governme… | GMREGlobal Medical RE… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.51x | 0.48x |
| 52-Week HighHighest price in past year | $24.94 | $39.93 |
| 52-Week LowLowest price in past year | $19.82 | $29.05 |
| % of 52W HighCurrent price vs 52-week peak | +93.4% | +89.5% |
| RSI (14)Momentum oscillator 0–100 | 53.5 | 52.7 |
| Avg Volume (50D)Average daily shares traded | 386K | 115K |
Evenly matched — DEA and GMRE each lead in 1 of 2 comparable metrics.
Analyst Outlook
GMRE leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Wall Street rates DEA as "Hold" and GMRE as "Buy". Consensus price targets imply 11.9% upside for GMRE (target: $40) vs -29.5% for DEA (target: $16). For income investors, GMRE offers the higher dividend yield at 63.51% vs DEA's 9.01%.
| Metric | DEAEasterly Governme… | GMREGlobal Medical RE… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $16.41 | $40.00 |
| # AnalystsCovering analysts | 8 | 22 |
| Dividend YieldAnnual dividend ÷ price | +9.0% | +63.5% |
| Dividend StreakConsecutive years of raises | 0 | 5 |
| Dividend / ShareAnnual DPS | $2.10 | $22.70 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
GMRE leads this category, winning 2 of 2 comparable metrics.
Key Takeaway
GMRE leads in 3 of 6 categories (Valuation Metrics, Total Returns). DEA leads in 1 (Income & Cash Flow). 2 tied.
Best OverallGlobal Medical REIT Inc. (GMRE)Leads 3 of 6 categories
Loading custom metrics...
DEA vs GMRE: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is DEA or GMRE a better buy right now?
For growth investors, Easterly Government Properties, Inc.
(DEA) is the stronger pick with 11. 3% revenue growth year-over-year, versus -1. 8% for Global Medical REIT Inc. (GMRE). Easterly Government Properties, Inc. (DEA) offers the better valuation at 80. 3x trailing P/E (69. 5x forward), making it the more compelling value choice. Analysts rate Global Medical REIT Inc. (GMRE) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DEA or GMRE?
On trailing P/E, Easterly Government Properties, Inc.
(DEA) is the cheapest at 80. 3x versus Global Medical REIT Inc. at 115. 3x. On forward P/E, Easterly Government Properties, Inc. is actually cheaper at 69. 5x.
03Which is the better long-term investment — DEA or GMRE?
Over the past 5 years, Global Medical REIT Inc.
(GMRE) delivered a total return of -19. 8%, compared to -37. 9% for Easterly Government Properties, Inc. (DEA). Over 10 years, the gap is even starker: GMRE returned +308. 1% versus DEA's -10. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DEA or GMRE?
By beta (market sensitivity over 5 years), Global Medical REIT Inc.
(GMRE) is the lower-risk stock at 0. 48β versus Easterly Government Properties, Inc. 's 0. 51β — meaning DEA is approximately 6% more volatile than GMRE relative to the S&P 500. On balance sheet safety, Global Medical REIT Inc. (GMRE) carries a lower debt/equity ratio of 118% versus 123% for Easterly Government Properties, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — DEA or GMRE?
By revenue growth (latest reported year), Easterly Government Properties, Inc.
(DEA) is pulling ahead at 11. 3% versus -1. 8% for Global Medical REIT Inc. (GMRE). On earnings-per-share growth, the picture is similar: Easterly Government Properties, Inc. grew EPS -37. 0% year-over-year, compared to -94. 6% for Global Medical REIT Inc.. Over a 3-year CAGR, GMRE leads at 6. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DEA or GMRE?
Global Medical REIT Inc.
(GMRE) is the more profitable company, earning 4. 8% net margin versus 3. 9% for Easterly Government Properties, Inc. — meaning it keeps 4. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DEA leads at 24. 9% versus 23. 6% for GMRE. At the gross margin level — before operating expenses — GMRE leads at 78. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DEA or GMRE more undervalued right now?
On forward earnings alone, Easterly Government Properties, Inc.
(DEA) trades at 69. 5x forward P/E versus 595. 7x for Global Medical REIT Inc. — 526. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMRE: 11. 9% to $40. 00.
08Which pays a better dividend — DEA or GMRE?
All stocks in this comparison pay dividends.
Global Medical REIT Inc. (GMRE) offers the highest yield at 63. 5%, versus 9. 0% for Easterly Government Properties, Inc. (DEA).
09Is DEA or GMRE better for a retirement portfolio?
For long-horizon retirement investors, Global Medical REIT Inc.
(GMRE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48), 63. 5% yield, +308. 1% 10Y return). Both have compounded well over 10 years (GMRE: +308. 1%, DEA: -10. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DEA and GMRE?
Both stocks operate in the Real Estate sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(DEA: 10.6% · GMRE: 18.7%)P/E Ratio<
x
(DEA: 80.3x · GMRE: 115.3x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.